Novel Directions in HIV-1 Vaccines Revealed from Clinical Trials

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2013 Jun 8

PMID 23743791

Citations 25

Authors

Jean-Louis Excler

Georgia D Tomaras

Nina D Russell

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Considerable HIV-1 vaccine development efforts have been deployed over the past decade. Put into perspective, the results from efficacy trials and the identification of correlates of risk have opened large and unforeseen avenues for vaccine development.

Recent Findings: The Thai efficacy trial, RV144, provided the first evidence that HIV-1 vaccine protection against HIV-1 acquisition could be achieved. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop inversely correlated with a decreased risk of infection, whereas Env-specific IgA directly correlated with risk. Further clinical trials will focus on testing new envelope subunit proteins formulated with adjuvants capable of inducing higher and more durable functional antibody responses (both binding and broadly neutralizing antibodies). Moreover, vector-based vaccine regimens that can induce cell-mediated immune responses in addition to humoral responses remain a priority.

Summary: Future efficacy trials will focus on prevention of HIV-1 transmission in heterosexual population in Africa and MSM in Asia. The recent successes leading to novel directions in HIV-1 vaccine development are a result of collaboration and commitment among vaccine manufacturers, funders, scientists and civil society stakeholders. Sustained and broad collaborative efforts are required to advance new vaccine strategies for higher levels of efficacy.

Citing Articles

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers.

Msafiri F, Joachim A, Held K, Nadai Y, Chissumba R, Geldmacher C Microorganisms. 2020; 8(11).

PMID: 33158007 PMC: 7693996. DOI: 10.3390/microorganisms8111722.

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

Levy Y, Lacabaratz C, Ellefsen-Lavoie K, Stohr W, Lelievre J, Bart P PLoS Pathog. 2020; 16(6):e1008522.

PMID: 32589686 PMC: 7319597. DOI: 10.1371/journal.ppat.1008522.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas E, Kroidl A, Munseri P, Missanga M, Nilsson C, Tembe N PLoS One. 2018; 13(11):e0206838.

PMID: 30496299 PMC: 6264478. DOI: 10.1371/journal.pone.0206838.

Correlates of GLA family adjuvants' activities.

Reed S, Carter D, Casper C, Duthie M, Fox C Semin Immunol. 2018; 39:22-29.

PMID: 30366662 PMC: 6289613. DOI: 10.1016/j.smim.2018.10.004.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas E, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O AIDS Res Hum Retroviruses. 2017; 34(2):193-205.

PMID: 28969431 PMC: 6913121. DOI: 10.1089/AID.2017.0121.

References

Koblin B, Casapia M, Morgan C, Qin L, Wang Z, Defawe O . Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One. 2011; 6(9):e24517. PMC: 3171485. DOI: 10.1371/journal.pone.0024517. View

Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J . Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine. 2008; 26(51):6671-7. DOI: 10.1016/j.vaccine.2008.09.016. View

Nakamura G, Fonseca D, ORourke S, Vollrath A, Berman P . Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One. 2012; 7(6):e39045. PMC: 3374778. DOI: 10.1371/journal.pone.0039045. View

Mehendale S, Sahay S, Thakar M, Sahasrabuddhe S, Kakade M, Shete A . Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Indian J Med Res. 2010; 132:168-75. View

van Griensven F, de Lind van Wijngaarden J . A review of the epidemiology of HIV infection and prevention responses among MSM in Asia. AIDS. 2010; 24 Suppl 3:S30-40. DOI: 10.1097/01.aids.0000390087.22565.b4. View

Excler J, Plotkin S . The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997; 11 Suppl A:S127-37. View

Sanders E, Okuku H, Smith A, Mwangome M, Wahome E, Fegan G . High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS. 2012; 27(3):437-46. PMC: 3929859. DOI: 10.1097/QAD.0b013e32835b0f81. View

B Gilbert P, Ackers M, Berman P, Francis D, Popovic V, Hu D . HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005; 192(6):974-83. DOI: 10.1086/432734. View

Walsh S, Seaman M, Grandpre L, Charbonneau C, Yanosick K, Metch B . Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine. 2012; 31(1):114-9. PMC: 3566524. DOI: 10.1016/j.vaccine.2012.10.093. View

10.

Ramanathan V, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan P, Solomon S . A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009; 25(11):1107-16. DOI: 10.1089/aid.2009.0096. View

11.

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

12.

Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P . The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine. 2009; 28(2):371-8. DOI: 10.1016/j.vaccine.2009.10.038. View

13.

Padian N, McCoy S, Manian S, Wilson D, Schwartlander B, Bertozzi S . Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr. 2011; 58(2):e23-8. DOI: 10.1097/QAI.0b013e318227af37. View

14.

Perreau M, Welles H, Harari A, Hall O, Martin R, Maillard M . DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol. 2011; 85(19):9854-62. PMC: 3196391. DOI: 10.1128/JVI.00788-11. View

15.

Tartaglia J, Excler J, Habib R, Limbach K, Meignier B, Plotkin S . Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses. 1998; 14 Suppl 3:S291-8. View

16.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer R . The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012; 28(11):1444-57. PMC: 3484815. DOI: 10.1089/aid.2012.0103. View

17.

Duerr A, Huang Y, Buchbinder S, Coombs R, Sanchez J, Del Rio C . Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012; 206(2):258-66. PMC: 3490694. DOI: 10.1093/infdis/jis342. View

18.

Vasan S, Schlesinger S, Chen Z, Hurley A, Lombardo A, Than S . Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One. 2010; 5(1):e8816. PMC: 2810329. DOI: 10.1371/journal.pone.0008816. View

19.

Zolla-Pazner S, deCamp A, Cardozo T, Karasavvas N, Gottardo R, Williams C . Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013; 8(1):e53629. PMC: 3547933. DOI: 10.1371/journal.pone.0053629. View

20.

Plotkin S, Plotkin S . The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011; 9(12):889-93. DOI: 10.1038/nrmicro2668. View